June 04, 2023

Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades

In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.

Dana-Farber

August 12, 2023

The Use of Tubular Retractors to Access Deep Brain Lesions

Johns Hopkins neurosurgeon Raj Mukherjee discusses the use of tubular retractors to access deep brain lesions.

Johns Hopkins Medicine

September 29, 2023

New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines

In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.

Dana-Farber

November 21, 2023

Focusing in on Medulloblastoma

Clinicians and scientists at Johns Hopkins All Children’s Hospital collaborated to identify the oncogene that is responsible for causing group three medulloblastomas in children.

Johns Hopkins Medicine

January 25, 2023

Outcomes in Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Curative-Intent Treatment

In a study reported in the Journal of Clinical Oncology, Erker et al identified factors associated with better postrelapse survival among infants and young children with medulloblastoma relapsing afte...

The ASCO Post

September 18, 2023

Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology.

Dana-Farber

May 15, 2023

Cracking Glioblastoma’s Deadly Code: Research Focused on Improving Diagnosis and Genomics to Revolutionize Care

Even with growing awareness of the devastating effects of glioblastoma, the most common and aggressive form of brain cancer, treatment options remain limited and patients typically survive just 15-18 months beyond diagnosis. Researchers at the Miami Cancer Institute and Miami Neuroscience Institute, part of Baptist Health South Florida, are focusing their efforts to advance understanding of the disease and improve diagnostic, prognostic, and therapeutic outcomes.

Baptist Health South Florida

November 21, 2023

Paving the Way to New Treatment for Non-Small Cell Lung Cancer that Has Spread to the Brain

Multi-institutional study found that V12 Gy given to radiosurgical volume of larger than 10 cm3 , was a significant predictor of radiation necrosis in patients with brain metastasis from non-small cell lung cancer

Baptist Health South Florida

February 06, 2024

Miami Cancer Institute Publication Analyzes Role of Tissue-Agnostic Therapies for the Treatment of Primary Brain Tumors

Researchers from Miami Cancer Institute, part of Baptist Health South Florida, recently published a study in Trends in Cancer that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs). The publication describes the current and potential impact of tissue-agnostic therapies on the management of PBTs. As part of the publication, the researchers discuss data from clinical trials of tissue-agnostic targets for PBTs in the context of challenges in managing these tumors. They also describe additional tissue-agnostic targets that hold promise for benefiting patients with PBTs.

Baptist Health South Florida